Skip to main content

Protein-Based Nanosystems: Virus-Like-Particles in Modern Vaccine Development

Buy Article:

$105.00 plus tax (Refund Policy)

Protein-based nanosystems ranging from 8 to 50 nm in size offer novel immunotherapeutic opportunities in the treatment of cancer and chronic infectious diseases. Consisting of viral major coat or core proteins derived from viruses such as papillomavirus, polyomavirus, parvovirus, or hepatitis B virus, recombinant virus-like-particles spontaneously assemble into highly ordered, supramolecular structures. Employing genetic engineering or biochemical cross-linking, these nanostructures successfully serve as carrier matrix for the delivery of epitopes, protein fragments or complete proteins, with the added value of a strong inherent adjuvant activity. Therapeutic intervention against cancer relies on the breaking of T and B cell tolerance, which represents one of the key features of virus-like-particles serving as antigen delivery system. An ever increasing identification of validated target antigens from pathogens and tumors is paralleled by significant progress in bioprocess development. Virus-like-particles are ideal vehicles for the development of novel treatment concepts against many malignant and infectious diseases.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: ANTIGEN DELIVERY; CANCER; INFECTIOUS DISEASES; NANOBIOTECHNOLOGY; NANOPARTICLES; VACCINES; VIRUS-LIKE-PARTICLES

Document Type: Review Article

Publication date: 2006-10-01

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more